What is Idiopathic pulmonary fibrosis?
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease characterized by scarring and thickening of the tissue deep in the lungs. The word “idiopathic” means the exact cause is unknown, while “pulmonary fibrosis” refers to the formation of scar tissue in the lungs that makes breathing increasingly difficult. IPF primarily affects adults over 50 years of age, with men being slightly more affected than women. With a prevalence of approximately 3-9 cases per 100,000 people, IPF is considered a rare disease that significantly impacts quality of life and has a generally poor prognosis without treatment.
Key statistics
| Prevalence | 3-9 per 100,000 people |
| Age of onset | Typically over 50 years, peak 60-70 years |
| Gender ratio | Men affected 1.5-2 times more than women |
| 5-year survival | Approximately 50-70% with current treatments |
Symptoms
Primary symptoms: Progressive shortness of breath (dyspnea), persistent dry cough, fatigue, chest discomfort, clubbing of fingers and toes.
The hallmark symptom of IPF is progressive dyspnea that initially occurs only during physical exertion but gradually worsens to affect daily activities and eventually occurs at rest. A persistent, dry, hacking cough is often the first symptom patients notice, sometimes preceding breathlessness by months or years. Fatigue becomes increasingly prominent as the disease progresses, limiting patients’ ability to maintain their usual activities.
Physical examination typically reveals characteristic “Velcro crackles” – fine, dry crackling sounds heard through a stethoscope that resemble the sound of Velcro being pulled apart. Digital clubbing, where fingertips and toes become enlarged and rounded, develops in 25-50% of patients. Chest discomfort and weight loss may occur in advanced stages. Some patients also experience gastroesophageal reflux, which may worsen the cough and potentially contribute to disease progression.
Causes and risk factors
The exact cause of IPF remains unknown, hence the term “idiopathic.” However, the condition can occur in both sporadic (isolated) and familial forms. Familial pulmonary fibrosis accounts for approximately 5-10% of cases and suggests genetic predisposition, with mutations identified in genes such as TERT, TERC, SFTPC, and SFTPA2.
Major risk factors include advanced age (most cases occur after age 50), male gender, and cigarette smoking history. Environmental exposures to metal dust, wood dust, stone dust, and certain occupational hazards may increase risk. Gastroesophageal reflux disease (GERD) is found in up to 90% of IPF patients and may contribute to disease development or progression. Viral infections, including Epstein-Barr virus and cytomegalovirus, have been suggested as potential triggers, though evidence remains inconclusive.
Prevention
Currently, there are no proven methods to prevent IPF, as the underlying cause remains unknown. For individuals with familial pulmonary fibrosis, genetic counseling may be beneficial to understand inheritance patterns and discuss family planning options. Genetic testing is available for known mutations but is primarily recommended when there is a strong family history of pulmonary fibrosis.
General lung health measures may be beneficial, including smoking cessation, avoiding known environmental lung irritants, managing gastroesophageal reflux if present, and staying up-to-date with vaccinations to prevent respiratory infections. Regular medical check-ups are important for those with family history or other risk factors, though routine screening for asymptomatic individuals is not currently recommended.
Complications
Without treatment, IPF typically progresses relentlessly, leading to severe respiratory failure and death within 3-5 years of diagnosis. Acute exacerbations can occur, characterized by sudden worsening of symptoms and new lung injury, often triggered by infections, procedures, or unknown factors.
Progressive respiratory failure develops as lung scarring advances, eventually requiring supplemental oxygen and possibly mechanical ventilation. Pulmonary hypertension commonly develops due to scarring of lung blood vessels, placing additional strain on the heart and potentially leading to right heart failure. Secondary complications include increased susceptibility to respiratory infections, pneumothorax (collapsed lung), and lung cancer, which occurs at higher rates in IPF patients than the general population.
Diagnosis
Diagnosing IPF requires a multidisciplinary approach combining clinical presentation, imaging findings, and sometimes lung biopsy. High-resolution computed tomography (HRCT) of the chest is the most important diagnostic tool, showing the characteristic “usual interstitial pneumonia” (UIP) pattern with honeycombing, traction bronchiectasis, and peripheral, basal-predominant fibrosis.
Pulmonary function tests reveal restrictive patterns with reduced lung volumes and impaired gas exchange. The six-minute walk test assesses functional capacity and oxygen requirements. Blood tests help exclude other conditions and may include autoimmune markers, complete blood count, and inflammatory markers.
When imaging is not definitively diagnostic, lung biopsy may be necessary, either through bronchoscopy (transbronchial biopsy) or surgical biopsy (video-assisted thoracoscopic surgery). The diagnosis requires exclusion of other known causes of pulmonary fibrosis and confirmation of the UIP pattern either radiologically or histologically.
Treatment
Two antifibrotic medications are approved for IPF treatment: pirfenidone and nintedanib. Both drugs slow disease progression and reduce the rate of lung function decline, though they do not cure the disease or significantly improve existing symptoms.
Supportive care is crucial and includes supplemental oxygen therapy for hypoxemia, pulmonary rehabilitation to improve exercise tolerance and quality of life, and treatment of gastroesophageal reflux. Cough suppressants may provide symptomatic relief for persistent cough.
Lung transplantation remains the only definitive treatment for end-stage disease and should be considered early in appropriate candidates. Corticosteroids and other immunosuppressive drugs are generally not recommended and may be harmful. Clinical trials investigating new therapeutic approaches are ongoing and may provide additional treatment options.
Prognosis
Historically, IPF had a median survival of 3-5 years from diagnosis, worse than many cancers. With current antifibrotic treatments, prognosis has improved somewhat, with 5-year survival rates now approaching 50-70% in some studies. However, the disease course remains unpredictable, with some patients experiencing rapid progression while others have slower decline.
Prognostic factors include age at diagnosis, extent of disease on imaging, degree of functional impairment, and response to treatment. Acute exacerbations significantly worsen prognosis. Earlier diagnosis and treatment initiation are associated with better outcomes, emphasizing the importance of prompt evaluation for suspected cases.
Quality of life
IPF significantly impacts daily living, with progressive breathlessness limiting physical activities and affecting independence. Patients should work with healthcare teams to develop individualized exercise programs, as pulmonary rehabilitation can improve exercise tolerance and reduce symptoms.
Energy conservation techniques help manage fatigue, including pacing activities and using assistive devices. Nutritional counseling addresses weight loss and maintains strength. Sleep quality may be affected by breathlessness and coughing, potentially requiring oxygen therapy or cough management.
Mental health support is crucial, as IPF commonly causes anxiety and depression. Support groups, either in-person or online, connect patients with others facing similar challenges. Advance care planning discussions help patients and families prepare for disease progression and make informed decisions about future care.
Pregnancy and fertility
IPF rarely affects women of childbearing age, but when it does, pregnancy poses significant risks due to increased metabolic demands and reduced respiratory reserve. The safety of antifibrotic medications during pregnancy is not well-established, and treatment decisions require careful consideration of maternal and fetal risks.
Fertility is not directly affected by IPF, but the physical limitations and medications may impact family planning decisions. Women with IPF considering pregnancy should undergo thorough pre-conception counseling with pulmonologists and maternal-fetal medicine specialists. Close monitoring throughout pregnancy is essential for both maternal and fetal wellbeing.
Children
IPF is extremely rare in children, with pediatric interstitial lung disease representing a different spectrum of conditions. When familial pulmonary fibrosis is diagnosed in adults, genetic counseling for family members, including children, may be appropriate to assess risk and discuss monitoring strategies.
Children of parents with familial pulmonary fibrosis may benefit from genetic testing and, if positive, long-term follow-up with pediatric pulmonologists, though specific screening protocols are not well-established.
When to see a doctor
Seek immediate medical attention for sudden worsening of breathlessness, chest pain, or signs of respiratory distress. Routine medical evaluation is warranted for persistent unexplained cough lasting more than 8 weeks, progressive shortness of breath, or fatigue that interferes with daily activities.
Individuals with family history of pulmonary fibrosis should discuss screening and genetic counseling with their healthcare providers. Regular follow-up with pulmonologists is essential for diagnosed patients to monitor disease progression and adjust treatments.
Regional context
Limited data exists on IPF prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. Regional environmental factors, genetic backgrounds, and healthcare access may influence disease prevalence and outcomes. We invite regional pulmonologists and researchers to contribute data on IPF epidemiology and clinical experience in these regions to Global Medical Journal.
Research and clinical trials
Active research focuses on novel antifibrotic agents, anti-inflammatory treatments, and regenerative therapies. Promising approaches include autotaxin inhibitors, integrin antagonists, and stem cell therapies. Biomarker research aims to improve early diagnosis and monitor treatment response.
Current clinical trials investigate combination therapies, new drug targets, and precision medicine approaches based on genetic and molecular profiling. Patients interested in clinical trials can search ClinicalTrials.gov for opportunities and should discuss participation with their healthcare teams.
Frequently asked questions
Is IPF contagious?
No, IPF is not contagious and cannot be transmitted from person to person. It is an internal scarring process of unknown cause.
Will antifibrotic drugs cure my IPF?
Current medications slow progression but do not cure IPF or reverse existing scarring. They can help preserve lung function and improve quality of life.
Can I exercise with IPF?
Yes, appropriate exercise is beneficial and recommended. Pulmonary rehabilitation programs can help develop safe, effective exercise routines tailored to individual capabilities.
How quickly does IPF progress?
Progression varies significantly between individuals. Some patients decline rapidly while others have slower progression over years. Regular monitoring helps track changes.
Should my family members be tested for IPF?
Family members of patients with familial pulmonary fibrosis may benefit from genetic counseling and possibly genetic testing, especially if multiple family members are affected.
Support and resources
- Pulmonary Fibrosis Foundation: pulmonaryfibrosis.org
- EURORDIS (European Organisation for Rare Diseases): eurordis.org
- National Organization for Rare Disorders (NORD): rarediseases.org
- Orphanet: orpha.net
- World Health Organization: who.int
Related conditions
- Nonspecific interstitial pneumonia
- Hypersensitivity pneumonitis
- Sarcoidosis
- Connective tissue disease-associated interstitial lung disease
- Asbestosis
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Idiopathic pulmonary fibrosis.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/idiopathic-pulmonary-fibrosis/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?